AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Beta-1,3-galactosyltransferase 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96L58

UPID:

B3GT6_HUMAN

Alternative names:

GAG GalTII; Galactosyltransferase II; Galactosylxylosylprotein 3-beta-galactosyltransferase; UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6

Alternative UPACC:

Q96L58; Q5T7M5

Background:

Beta-1,3-galactosyltransferase 6, known alternatively as GAG GalTII, Galactosyltransferase II, and Galactosylxylosylprotein 3-beta-galactosyltransferase, plays a pivotal role in the biosynthesis of glycosaminoglycans. This enzyme specifically transfers galactose from UDP-galactose to substrates with terminal beta-linked galactose residues, showing a preference for galactose-beta-1,4-xylose found in heparan sulfate and chondroitin sulfate.

Therapeutic significance:

Given its crucial role in the synthesis of glycosaminoglycans, Beta-1,3-galactosyltransferase 6 is implicated in several genetic disorders, including Ehlers-Danlos syndrome, spondylodysplastic type, 2, Spondyloepimetaphyseal dysplasia with joint laxity, and Al-Gazali syndrome. Understanding the enzyme's function could lead to novel therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.